Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2021 | Real-world data for nivo in recurrent malignant pleural mesothelioma

Robin Cornelissen, MD, PhD, Erasmus University Medical Center, Rotterdam, The Netherlands, discusses a real-world analysis of patients with progressive malignant pleural mesothelioma (MPM) receiving nivolumab, an anti-PD-1 monoclonal antibody which showed promising activity in Phase II clinical trials. Patients participating in the BMS-sponsored Expanded Access Program from both the Erasmus Medical Center and The Netherlands Cancer Institute cohorts were included in the analysis. Over 100 patients treated with nivolumab and evaluated via CT were identified. The overall response rate (ORR) and median overall survival (mOS) were found to be lower than those seen in clinical trials of checkpoint inhibitors. In the 10 patients who did achieve a partial response, mOS was significantly improved and no deaths were reported after 14 months of follow up. PD-L1 positivity was found to be associated with an improved ORR and may represent a useful biomarker for nivolumab treatment. This interview took place during the IASLC World Conference on Lung Cancer (WCLC) virtual meeting 2021.